Saint Luke's Newsroom

Sep. 23, 2021

KMBC: Kansas City doctors push people to get flu shots as pandemic continues

Dr. Todd Fristo, family medicine physician at Saint Luke's Physician Group, talks about the importance of the flu vaccine this year. 
Sep. 22, 2021

KBIA: Missouri OBGYNs Are Worried About Rise in Severe Complications, Stillbirths in COVID-19 Positive Mothers

KBIA talked to Dr. Rebecca Hamel about the risks expecting mothers face with COVID-19 and why all women who are pregnant or hoping to become pregnant should get the vaccine as soon as possible. 
Sep. 20, 2021

KSHB: Saint Luke's OBGYN pleads with expecting mothers to get vaccinated as many end up in ICU

KSHB talked to Dr. Rebecca Hamel about why pregnant mothers should get vaccinated as soon as possible with increased risks due to the emergence of the delta variant.
Sep. 20, 2021

Today Online: How much exercise do we need to live longer?

To increase our chances for a long life, we probably should take at least 7,000 steps a day or play sports such as tennis, cycling, swimming, joggi

Sep. 17, 2021

Healio: PRESERVED-HF: Dapagliflozin improves HFpEF symptoms at 12 weeks

Dapagliflozin improved symptoms and physical limitations in patients with heart failure (HF) with preserved ejection fraction, according to results from the PRESERVED-HF trial.
Sep. 15, 2021

TCTMD: PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Dapagliflozin eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period.
Sep. 15, 2021

Cardiovascular Business: Dapagliflozin significantly improves HFpEF symptoms

Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.
Sep. 14, 2021

MD edge: PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF

The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more than 300 U.S. patients with heart failure with preserved ejection fraction (HFpEF).
Sep. 13, 2021

Medpage Today: SGLT2 Inhibitor Eases Symptoms for HFpEF Patients

Symptoms of heart failure with preserved ejection fraction (HFpEF) improved with dapagliflozin (Farxiga) therapy, the PRESERVED-HF trial showed.